Our PMD cohort had higher rates of PLP1 duplications (74.7%) and point mutations (22.0%), perhaps because our study did not include PLP1 null mutations or splice site mutations that most often lead to an SPG2 disorder [5, 19]. The gene discussed is PLP1; the disease is Pelizeaus-Merzbacher spectrum disorder.